What was the immediate impact on population health of the recent fall in hormone replacement therapy prescribing in England? Ecological study

Journal of Public Health

Volumn 32, Issue 4, 2010, Pages 555-564

  Martin, Richard M ^a   Wheeler, Benedict W ^a   Metcalfe, Chris ^a   Gunnell, David ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

breast cancer; colorectal cancer; drug regulations; endometrial cancer; England; hip fracture; hormone replacement therapy; myocardial infarction; stroke; trends; venous thromboembolism

Indexed keywords

AGED; ARTICLE; BREAST TUMOR; CLINICAL PRACTICE; COLORECTAL TUMOR; CONFIDENCE INTERVAL; ENDOMETRIUM TUMOR; FEMALE; HEALTH SURVEY; HEART INFARCTION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MIDDLE AGED; MORTALITY; STROKE; UNITED KINGDOM; UTILIZATION REVIEW; VENOUS THROMBOEMBOLISM;

AGED; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; ENDOMETRIAL NEOPLASMS; ENGLAND; FEMALE; HIP FRACTURES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; POPULATION SURVEILLANCE; STROKE; VENOUS THROMBOEMBOLISM;

EID: 78649542893     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fdq021     Document Type: Article

References (38)

1. Heiss G, Wallace R, Anderson GL et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299(9):1036-45.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288(3):321-33.
3. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004;291(14):1701-12.
4. Medicines Control Agency (MCA)/Committee on Safety of Medicines. New product information for hormone replacement therapy. Curr Probl Phamacovigilance 2002;28:1-2.
5. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362(9382):419-27.
6. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007;63(9):843-9.
7. Vankrunkelsven P, Kellen E, Lousbergh D et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 2009;118:425-32.
8. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008;107(3):427-30.
9. Canfell K, Banks E, Moa AM et al. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008;188(11):641-4.
10. Ravdin PM, Cronin KA, Howlader N et al. The decrease in breastcancer incidence in 2003 in the United States. N Engl J Med 2007;356(16):1670-4.
11. Glass AG, Lacey JV Jr, Carreon JD et al. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99(15):1152-61.
12. Shetty KD, Vogt WB, Bhattacharya J. Hormone replacement therapy and cardiovascular health in the United States. Med Care 2009;47(5):600-6.
13. Department of Health. Hospital Episode Statistics Database. 2007. www.hesonline.org.uk.
14. Office for National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland. 2009; www.statistics.gov. uk/StatBase/Productasp?vlnk=601.
15. Kerlikowske K, Miglioretti DL, Buist D S M et al. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007;99(17):1335-9. (Pubitemid 47394172)
16. Clarke CA, Glaser SL, Uratsu CS et al. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006;24(33):e49-e50.
17. Jemal A, Ward E, Thun M. Recent trends in breast cancer incidence rates by age and tumor characteristics among U. S. women. Breast Cancer Res 2007;9(3):R28.
18. Coombs NJ, Taylor R, Wilcken N et al. HRT and breast cancer: impact on population risk and incidence. Eur J Cancer 2005;41(12):1775-81.
19. Brewster DH, Sharpe KH, Clark DI et al. Declining breast cancer incidence and decreased HRT use. Lancet 2009;373(9662):459-60.
20. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 2008;372(9639):608-10.
21. Bluming AZ, Elfenbein GJ, Kliewer EV et al. A decline in breastcancer incidence. N Engl J Med 2007;357(5):509-13.
22. National Board of Health and Welfare (Socialstyrelsen). Cancer Incidence in Sweden 2005. Stockholm, 2007.
23. Soerjomataram I, Coebergh JW, Louwman M W J et al. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands? J Clin Oncol 2007;25(31):5038-9.
24. Nancy B, Kathleen AC, Helen IM et al. Reported drop in mammography. Cancer 2007;109:2405-9.
25. MacMahon B, Cole P. Is the incidence of breast cancer declining? Epidemiology 2008;19(2):268-9.
26. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 2009;45(9):1649-53.
27. Howe HL, Wu X, Ries LA et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U. S. Hispanic/Latino populations. Cancer 2006;107:1711-42.
28. Lundberg V, Tolonen H, Stegmayr B et al. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas 2004;48(1):39-49.
29. Bromley SE, de Vries CS, Farmer R D T. Utilisation of hormone replacement therapy in the United Kingdom. BJOG 2004;111:369-76.
30. Blanks RG, Bennett RL, Patnick J et al. The effect of changing from one to two views at incident (subsequent) screens in the NHS breast screening programme in England: impact on cancer detection and recall rates. Clin Radiol 2005;60(6):674-80.
31. Grady D, Gebretsadik T, Kerlikowske K et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obst Gynecol 1995;85(2):304-13.
32. Hulley S, Furberg C, Barrett-Connor E et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288(1):58-64.
33. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288(1):49-57. (Pubitemid 34705518)
34. International Agency for Research on Cancer. Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy. Lyon: International Agency for Research on Cancer, 2007.
35. Cauley JA, Robbins J, Chen Z et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women's health initiative randomized trial. JAMA 2003;290(13):1729-38.
36. Ettinger B, Woods NF, Barrett-Connor E et al. The North American Menopause Society 1998 Menopause Survey: Part II. Counseling about hormone replacement therapy: association with socioeconomic status and access to medical care. Menopause 2000;7(3):143-8.
37. Banks E, Canfell K. Invited commentary: hormone therapy risks and benefits-the women's health initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol 2009;170(1):24-8.
38. Hulley SB, Grady D. The WHI estrogen-alone trial-do things look any better? JAMA 2004;291(14):1769-71.